Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Expression from second-generation feline immunodeficiency virus vectors is impaired in human hematopoietic cells.

Mary A Price1, Scott S Case, Denise A Carbonaro

  • 1Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, Los Angeles, California 90027, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|November 1, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Newborn screening reduces survival disparities in SCID after stem cell transplant: A PIDTC report.

Journal of human immunity·2026
Same author

Response to "Defining durability in SCD gene therapy".

Blood advances·2026
Same author

Long-term stability of posttranscriptional genetic silencing of BCL11A using a shmiR vector in Sickle Cell Disease.

Blood·2026
Same author

Clinical Outcomes of Lentiviral Vector Gene Therapy for Sickle Cell Disease.

Blood advances·2026
Same author

A blueprint to accelerate rare pediatric gene therapy approvals.

Nature medicine·2026
Same author

Neurodevelopmental outcomes following hematopoietic cell transplantation for patients with severe combined immunodeficiency (SCID): A PIDTC study.

Journal of human immunity·2026

Feline immunodeficiency virus (FIV) vectors efficiently transfer genes to human hematopoietic cells but show poor expression. Human immunodeficiency virus-1 (HIV-1) vectors demonstrate superior expression in these cells, indicating FIV backbone limitations.

Area of Science:

  • Gene therapy
  • Lentiviral vectors
  • Hematopoietic stem cell research

Background:

  • Feline immunodeficiency virus (FIV) vectors offer theoretical safety advantages over human immunodeficiency virus-1 (HIV-1) vectors.
  • Lentiviral vectors are crucial tools for gene transfer in hematopoietic stem cells.

Purpose of the Study:

  • To compare the gene transfer and expression efficiency of FIV-based and HIV-1-based lentiviral vectors.
  • To evaluate vector performance in human and feline hematopoietic progenitor cells.

Main Methods:

  • Utilized second-generation HIV-1 and FIV vectors, pseudotyped with VSV-G.
  • Tested vectors with human cytomegalovirus or PGK internal promoters.
  • Assessed gene transfer and expression in primary human/feline hematopoietic cells and cell lines.

Related Experiment Videos

Main Results:

  • Both HIV-1 and FIV vectors demonstrated efficient gene transfer, achieving similar proviral copy numbers in human and feline cells.
  • HIV-1 vectors exhibited robust transgene expression in human hematopoietic cells.
  • FIV vectors showed significantly lower transgene expression specifically in human hematopoietic cells, despite efficient gene transfer.

Conclusions:

  • FIV vectors can effectively deliver genes to human hematopoietic cells, comparable to HIV-1 vectors.
  • An unidentified element within the FIV vector backbone inhibits transgene expression in human hematopoietic cells.
  • Further research is needed to overcome FIV vector expression limitations in human hematopoietic stem cell applications.